Introduction: The Glulisine in Combination with Insulin Glargine in an Intensified Insulin Regimen (GINGER) study compared insulin glargine plus insulin glulisine with premixed insulin in the treatment of patients with Type 2 diabetes mellitus (T2DM). This was a post-hoc analysis of hypoglycaemia rates in subgroups from the GINGER study. Methods: This analysis compared the once-daily glargine plus mealtime glulisine group (n=153, four injections/day) with the overall twice-daily premixed insulin group (n=157, two injections/day), which consisted of two subgroups receiving either neutral protamine Hagedorn (NPH) plus regular insulin (n=93) or biphasic insulin aspart 70/30 (n=63). Observed and predicted hypoglycaemia rates relative to endpoint HbA 1c for both the total population and those patients who experienced ≥1 episodes of any hypoglycaemia were estimated. Results: The overall hypoglycaemic event rate (episodes per patient-year) for patients receiving glargine plus glulisine was numerically but not significantly lower (-24.5 %) compared with the overall premixed insulin group (14.0±24.2 versus 18.5±36.9; p=0.12) and significantly lower (-43.3 %) compared with the biphasic insulin aspart 70/30 subgroup (24.7±48.5; p=0.02). In patients with ≥1 episode of hypoglycaemia during treatment, the overall hypoglycaemic event rate was significantly lower (-26.5 %) in patients receiving glargine plus glulisine versus overall premixed insulin (18.5±26.3 versus 25.1±41.1; p=0.044) and significantly lower (-40.7 %) than in patients receiving biphasic insulin aspart 70/30 (31.1±52.7; p=0.009). Glargine/glulisine treatment maintained a more consistent and numerically lower hypoglycaemia rate at all achieved HbA 1c endpoints compared with premixed insulin treatment. Conclusion: This posthoc analysis of the GINGER study showed that the frequency of hypoglycaemia in T2DM patients was lowered to a greater extent by insulin glargine plus insulin glulisine in a comparison with premixed biphasic insulin aspart 70/30 than was previously shown in a comparison with overall premixed insulin. Trial Identifier: NCT00174668
The study demonstrated that an intensified basal-bolus regimen using insulin glargine plus insulin glulisine provided significantly better glycaemic control and numerically lower overall hypoglycaemia than premixed insulin therapy.
The premixed insulin group in the GINGER study comprised two subgroups: those taking neutral protamine Hagedorn (NPH) insulin plus regular insulin and those taking biphasic insulin aspart 70/30.
The aim of this post-hoc analysis was to determine the overall hypoglycaemic event rates in the insulin glargine plus insulin glulisine group with that of the premixed insulin subgroups, and to compare hypoglycaemia risk relative to the glycaemic control achieved at the end of the GINGER study.
Methods
Details of the study design and patient population have been published previously. 3 The primary endpoint of the GINGER study was the change in HbA1c from baseline to endpoint. Secondary endpoints included the rate of hypoglycaemia. A hypoglycaemic event was defined as an event with symptoms consistent with hypoglycaemia and/or a confirmed plasma glucose (PG) level ≤60 mg/dL (≤3.3 mmol/L).
For the post-hoc analysis, hypoglycaemic event rates (events per patient-year) were estimated for the total study population and for those patients who experienced ≥1 episodes of any hypoglycaemia, using a negative binomial regression model. 4 In addition, hypoglycaemia event rates were plotted against the endpoint HbA1c for each patient in each group or subgroup. All tests were adjusted for baseline HbA1c
and duration of diabetes. To account for the relatively large number of patients with no event, a logistic regression analysis was performed and the p values of both methods combined to form the adjusted p values reported for each treatment group.
Results
Overall, the total study population (n=310) was 49 % female, had a mean±SD age of 61±8 years and had a body mass index of 30.1±3.7 kg/ m². Mean duration of T2DM was 13±6 years, with mean insulin use of 5±4 years. Baseline HbA1c was 8.56±0.85%. The demographics and baseline characteristics of the two groups were well matched. 3 The glargine plus glulisine group had a greater change from baseline in both groups (data not shown).
Expected and observed hypoglycaemic event rates relative to endpoint HbA1c for the glargine plus glulisine group compared with the overall and biphasic aspart 70/30 premixed insulin subgroup are shown in Figures 1A and 1B , respectively. These graphs indicate that the glargine plus glulisine treatment maintains a numerically lower level of hypoglycaemic events over the entire range of HbA1c levels compared with the premixed insulin treatments, which showed higher hypoglycaemic event rates at lower HbA1c levels, but this declined at higher HbA1c levels. The graphs also show a more pronounced difference in the hypoglycaemic event rate between the glargine plus glulisine group and the biphasic insulin aspart 70/30 subgroup (graph B) at lower HbA1c levels than was observed between the glargine plus glulisine group and the overall premixed insulin group (graph A).
Discussion
In the GINGER study, rates of hypoglycaemic events were numerically, but not significantly, lower for patients taking once-daily insulin glargine plus mealtime insulin glulisine than for those taking twicedaily premixed insulin. 3 In this post-hoc analysis of the GINGER study, actual rates of overall hypoglycaemia were determined as a function of endpoint HbA1c for patients in each of the two groups. Using a negative binomial regression model, 4 the predicted rates for the basal-bolus group were compared with those of the overall premixed insulin group. Adjusting for endpoint HbA1c did not alter the original outcome between the glargine plus glulisine and the overall premixed insulin groups: overall hypoglycaemic events were numerically, but not significantly, lower for patients taking once-daily insulin glargine plus mealtime insulin glulisine.
A substantial number of patients in the two groups did not experience any hypoglycaemic events. When only those patients who experienced one or more events were analysed, the rate of hypoglycaemic events was significantly lower with glargine plus glulisine than with the overall premixed insulin group.
For the premixed insulin aspart subgroup, rates of overall hypoglycaemia were significantly greater than those of glargine plus glulisine whether all patients or only those who experienced a hypoglycaemic event were analysed.
Differences in dosing frequency between the glargine plus glulisine regimen (given as four injections daily) versus the premixed insulin regimen (given as two injections daily) were unlikely to have affected study endpoints.
Previous studies in inadequately controlled diabetes patients have
shown that dose intensification of premixed insulins does not appear to alter endpoint HbA1c levels or the incidence of hypoglycaemic events.
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The study results suggest that when both endpoint HbA1c and overall hypoglycaemic events are considered, a basal−bolus regimen with insulin glargine plus insulin glulisine has a better benefit-to-risk profile than premixed insulin therapy, especially than insulin aspart 70/30, in patients with T2DM. 4. Insulin glargine/glulisine treatment was associated with a numerically lower hypoglycaemia event rate that was maintained at all achieved HbA1c endpoints compared with premixed insulin treatment
